The dynamic and stress-adaptive signaling hub of 14-3-3: emerging mechanisms of regulation and context-dependent protein-protein interactions.
Pennington KL, Chan TY, Torres MP, Andersen JL. · 2018
Read The dynamic and stress-adaptive signaling hub of 14-3-3: emerging mechanisms of regulation and context-dependent protein-protein interactions. by Pennington KL, Chan TY, Torres MP, Andersen JL. (2018) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc6193947.txt.
Introduction
Pennington and co-authors wrote a review in Oncogene on the 14-3-3 proteins, a signaling hub inside cells. These proteins bind phosphorylated partners and regulate nearly every major cell function. Their web of interactions integrates many signaling pathways at once. In cancer they sit at the center of growth control.
Processes they govern include cell death, the cell cycle, autophagy, glucose use, and cell movement. Most known interactions were found in well-fed cell cultures. The review argues this underrates their reach under stress, such as lost nutrients or growth factors. New work shows how their binding changes with context. The authors chart this stress-adaptive hub and its grip on cancer behavior.
Catalog record
| CREATOR | Pennington KL, Chan TY, Torres MP, Andersen JL. |
|---|---|
| YEAR | 2018 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 97 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
The dynamic and stress-adaptive signaling hub of 14-3-3: emerging mechanisms of regulation and context-dependent protein–protein interactions By KL Pennington, TY Chan, MP Torres, JL Andersen Published in: Oncogene DOI: 10.1038/s41388-018-0348-3 ABSTRACT Abstract 14-3-3 proteins are a family of structurally similar phospho-binding proteins that regulate essentially every major cellular function. Decades of research on 14-3-3s have revealed a remarkable network of interacting proteins that demonstrate how 14-3-3s integrate and control multiple signaling pathways. In particular, these interactions place 14-3-3 at the center of the signaling hub that governs critical processes in cancer, including apoptosis, cell cycle progression, autophagy, glucose metabolism, and cell motility. Historically, the majority of 14-3-3 interactions have been identified and studied under nutrient-replete cell culture conditions, which has revealed important nutrient driven interactions. However, this underestimates the reach of 14-3-3s. Indeed, the loss of nutrients, growth factors, or changes in other environmental conditions (e.g., genotoxic stress) will not only lead to the loss of homeostatic 14-3-3 interactions, but also trigger new interactions, many of which are likely stress adaptive. This dynamic nature of the 14-3-3 interactome is beginning to come into focus as advancements in mass spectrometry are helping to probe deeper and identify context-dependent 14-3-3 interactions—providing a window into adaptive phosphorylation-driven cellular mechanisms that orchestrate the tumor cell’s response to a variety of environmental conditions including hypoxia and chemotherapy. In this review, we discuss emerging 14-3-3 regulatory mechanisms with a focus on post-translational regulation of 14-3-3 and dynamic protein–protein interactions that illustrate 14-3-3’s role as a stress-adaptive signaling hub in cancer. 14-3-3 FUNCTION The human 14-3-3 family consists of seven isoforms (β, γ, ε, η, σ, τ, and ζ), each expressed by a different gene. The multiplicity of 14-3-3 isoforms appears to be somewhat common throughout evolutionary history, as budding and fission yeast contain two different 14-3-3 genes, and plants express up to 15 different 14-3-3 isoforms. Other organisms, such as Dictyostelium discoideum and Giardia duodenalis, express only one 14-3-3 gene [1, 2]. In cases where multiple isoforms exist, 14-3-3s are thought to function as hetero- or homodimers, with each monomer consisting of nine α-helices that help form a highly conserved amphipathic groove that serves as the phosphorylation-binding pocket. Within this pocket, positively charged lysine and arginine residues (K49, K120, R56, and R127) coordinate an interaction with the phosphate of the binding partner. The same lysine residues may also serve as shut-off switches for 14-3-3 binding when modified by acetylation (discussed below) [3–5]. 14-3-3s interact with phosphorylated serines or threonines within the general consensus sequence RXXpS/TXP, although there are many examples that deviate from this motif. For example, the +2 proline occurs in just under half of the known 14-3-3 binding sites [6]. Phosphorylations on the target protein are frequently within regions of high intrinsic disorder and often occur in pairs with each phosphorylation interacting with a positively charged phospho-binding pocket on the 14-3-3 dimer. In some cases, a single phosphorylation is sufficient for 14-3-3 binding, while in others, two are required. Furthermore, when two phosphorylations are required for 14-3-3 binding, they may be added to the target protein by different kinase signaling pathways, which helps explain how 14-3-3s integrate multiple signaling pathways into a single output [7]. The effect of 14-3-3 docking to the phosphorylated protein can vary depending on the protein in question. 14-3-3 binding can mask nuclear localization or export signals, block binding of other proteins (e.g., phosphatases), or contort proteins into active or inhibited conformations (reviewed elsewhere [8, 9]). 14-3-3s may also act as molecular adapters by linking two phosphorylated proteins together [10]. The ability of 14-3-3 to alter the structure of its binding partners has been attributed to its rigid α-helical backbone, which may enforce conformational changes in the binding partner as 14-3-3 binds tightly around the phosphorylated docking sites. 14-3-3-MEDIATED CHEMORESISTANCE Most of the evidence supporting a role for 14-3-3s in promoting chemoresistance and poor patient outcomes focuses on the 14-3-3ζ gene (YWHAZ), which resides within the 8q22.3 chromosomal region which is frequently duplicated in cancer [11, 12]. 14-3-3ζ functions as a central node to promote oncogenic and chemoresistance pathways in cancer including PI3K/AKT, IGF-IR, ERK/MAPK, TGF-β, β-catenin, and hTERT [13–23]. Transgenic overexpression of 14-3-3ζ alone induces tumorigenesis in mice [23]. High levels of 14-3-3ζ expression have been correlated with poor patient outcomes in a variety of cancers, including breast, lung, multiple myeloma, head and neck, and glioblastoma [13, 14, 19, 24–29]. Cell culture studies provide further evidence that overexpression of 14-3-3ζ, as well as other 14-3-3 isoforms, confers chemoresistance. These 14-3-3 isoforms include 14-3-3γ in melanoma cells resistant to cisplatin, etoposide, fotemustine, or vindesine; 14-3-3ε in breast cancer cells resistant to adriamycin or paclitaxel; and 14-3-3ζ in diffuse large B-cell lymphoma (DLBCL) and prostate cancer cells [30–33]. 14-3-3ζ depletion has also been shown to sensitize non-small cell lung cancer cells to cisplatin treatment without affecting the proliferation or apoptosis rates of untreated cells in vitro, slow tumor growth in an animal model following cisplatin treatment, and restore sensitivity of DLBCL cells to CHOP-induced cell death [25, 32]. Disruption of 14-3-3-ligand interactions by treatment with the R18 peptide (described below) sensitizes BCR-Abl-transformed murine cells to U0126, GX15-070, and rapamycin-induced apoptosis [34]. Further, 14-3-3ζ overexpression reduced the sensitivity of prostate carcinoma cells to 9NC6 treatment, and 14-3-3ε overexpression protected colorectal carcinoma cells from NSAID-induced apoptosis [33, 35]. Recent evidence also suggests that 14-3-3ζ interacts with proteasome subunits and restrains proteasome activity in multiple myeloma cells, such that depletion of 14-3-3ζ increases proteasome activity and enhances the sensitivity of the cells to the proteasome inhibitor bortezomib [29]. Thus, published studies reinforce the idea that 14-3-3ζ, given its large network of pro-survival interactions, could potentially be targeted to sensitize cancer cells to a wide range of cell death-inducing therapeutics. As discussed below, although we have yet to see a 14-3-3 inhibitor in the clinic, current efforts are underway to develop small molecule disruptors of 14-3-3 interactions. 14-3-3S AS THERAPEUTIC TARGETS Although pharmaceutical efforts have traditionally focused on developing inhibitors of enzymes (e.g., kinases, G protein-coupled receptors), there has been a recent surge in targeting protein–protein interactions (PPIs). PPI inhibitors include a variety of promising cancer therapeutics such as SMAC and BH3 mimetics, p53-MDM2 antagonists, HSP90 inhibitors, and tubulin polymerization inhibitors [36]. 14-3-3s present an additional high-value target with the potential to disrupt a hub of pro-tumor pathways with a single hit. Historically, the dogma against developing PPI inhibitors has centered around the argument that PPIs often involve large protein surfaces with numerous residues contributing to the free energy of binding [37]. However, 14-3-3s present a well-defined phospho-peptide binding pocket with a relatively small number of positively charged residues (e.g., K49) required for binding, which makes them a seemingly attainable PPI target. Furthermore, for other phosphorylation driven PPIs, such as SH2-phosphotyrosine binding, the phosphate of the binding partner is thought to be the primary contributor of the free energy of binding [38]. Thus, small molecule disruption of even a single positively charged residue, like K49, within the 14-3-3 phospho-binding pocket, would likely abrogate 14-3-3 interactions. Several groups have focused on developing peptide and peptidomimetic inhibitors of 14-3-3s, which have been reviewed in detail elsewhere [39–42]. Among these are some notable leads. A phage display approach